Our experience in the diagnosis and treatment of peripheral exudative hemorrhagic chorioretinopathy

Our experience in the diagnosis and treatment of peripheral exudative hemorrhagic chorioretinopathy

Blog Article

Purpose: To present our experience in the examination and treatment of patients with peripheral exudative hemorrhagic chorioretinopathy (PEHCR).Material and Methods: We retrospectively reviewed the medical records of patients who were finally clinically diagnosed with PEHCR in the 2022-2023 period.History was collected and patients underwent ophthalmological examination including visual acuity, slit-lamp biomicroscopy, color fundus photography, fluorescein angiography and ocular ultrasound.All patients were treated with intravitreal anti-vascular endothelial milwaukee 2981-20 growth factor (VEGF) therapy.

One patient underwent vitreoretinal surgery.Results: PEHCR was diagnosed in 11 patients (13 eyes), including two patients diagnosed with bilateral lesions.Clinical signs identified included a dome-shaped hemorrhagic detachment of the peripheral retinal pigment epithelium (RPE) with massive exudations.One patient underwent vitreoretinal surgery for vitreoretinal hemorrhage.

On B-scan ultrasonography, the PEHCR lesion commonly presented as a dome or plateau-shaped mass with hollow or solid acoustic quality.Ten patients were treated with intravitreal aflibercept.Conclusion: PEHCR is a chronic disease commonly associated with AMD.Detachment of the peripheral RPE is a major clinical manifestation of the disease, and may be complicated by sub-RPE hemorrhage in early disease.

Anti-VEGF therapy is a major method of treatment whereas vitreoretinal surgery is indicated in complications accompanied by massive intravitreal hemorrhage or macula-threatening subretinal hemorrhage.Further investigation is needed to elucidate the dale duby obsidian knives etiology and pathogenesis of this entity and demonstrate the efficacy and safety of the aforementioned treatment modalities for PEHCR.